Only limited data exist on Pseudomonas aeruginosa ventilator-associated pneumonia (VAP) treated with imipenem, meropenem, or doripenem. Therefore, we conducted a prospective observational study in 169 patients who developed Pseudomonas aeruginosa VAP. Imipenem, meropenem, and doripenem MICs for Pseudomonas aeruginosa isolates were determined using Etests and compared according to the carbapenem received. Among the 169 isolates responsible for the first VAP episode, doripenem MICs were lower (P < 0.0001) than those of imipenem and meropenem (MIC 50 s, 0.25, 2, and 0.38, respectively); 61%, 64%, and 70% were susceptible to imipenem, meropenem, and doripenem, respectively (P was not statistically significant). Factors independently associated with carbapenem resistance were previous carbapenem use (within 15 days) and mechanical ventilation duration before VAP onset. Fifty-six (33%) patients had at least one VAP recurrence, and 56 (33%) died. Factors independently associated with an unfavorable outcome (recurrence or death) were a high day 7 sequential organ failure assessment score and mechanical ventilation dependency on day 7. Physicians freely prescribed a carbapenem to 88 patients: imipenem for 32, meropenem for 24, and doripenem for 32. The remaining 81 patients were treated with various antibiotics. Imipenem-, meropenem-, and doripenem-treated patients had similar VAP recurrence rates (41%, 25%, and 22%, respectively; P ‫؍‬ 0.15) and mortality rates (47%, 25%, and 22%, respectively; P ‫؍‬ 0.07). Carbapenem resistance emerged similarly among patients treated with any carbapenem. No carbapenem was superior to another for preventing carbapenem resistance emergence. P seudomonas aeruginosa, one of the main microorganisms responsible for ventilator-associated pneumonia (VAP) (1, 2), readily acquires antibiotic resistance, and each molecule is susceptible to several potential mechanisms of resistance. For example, carbapenem resistance can be due to the production of enzymes, such as AmpC or a metallo-␤-lactamase; overexpression of efflux pumps; porin deficiencies; or target site alterations (3-5). The rate of Pseudomonas aeruginosa carbapenem resistance is increasing (2), and one of the major risk factors for carbapenem resistance is carbapenem use (6, 7). Doripenem is a recent antipseudomonal carbapenem that exhibits greater in vitro activity against Pseudomonas aeruginosa isolates than other carbapenems and is less likely to select for carbapenem-resistant strains under experimental conditions (8-11). In one multicenter study, doripenem was shown to be noninferior to imipenem in patients with VAP, and the clinical cure rate was higher with doripenem than imipenem in patients with higher Acute Physiology and Chronic Health Evaluation II scores and older ages (12). However, a recent study found different results and raised doubts about the safety of doripenem compared to that of imipenem in patients with Pseudomonas aeruginosa VAP (13). Moreover, most studies that evaluated doripenem activity were in vitro studies, and uncertainty persists as to the capacity of a given carbapenem to select fewer carbapenem-resistant strains than another. In the Groupe Hospitalier Pitié-Salpêtrière, the three antipseudomonal carbapenems (imipenem, meropenem, and doripenem) are available and routinely prescribed by physicians in the two intensive care units (ICUs), where a local policy of mixing these three drugs is applied.
P
seudomonas aeruginosa, one of the main microorganisms responsible for ventilator-associated pneumonia (VAP) (1, 2) , readily acquires antibiotic resistance, and each molecule is susceptible to several potential mechanisms of resistance. For example, carbapenem resistance can be due to the production of enzymes, such as AmpC or a metallo-␤-lactamase; overexpression of efflux pumps; porin deficiencies; or target site alterations (3) (4) (5) . The rate of Pseudomonas aeruginosa carbapenem resistance is increasing (2) , and one of the major risk factors for carbapenem resistance is carbapenem use (6, 7) . Doripenem is a recent antipseudomonal carbapenem that exhibits greater in vitro activity against Pseudomonas aeruginosa isolates than other carbapenems and is less likely to select for carbapenem-resistant strains under experimental conditions (8) (9) (10) (11) . In one multicenter study, doripenem was shown to be noninferior to imipenem in patients with VAP, and the clinical cure rate was higher with doripenem than imipenem in patients with higher Acute Physiology and Chronic Health Evaluation II scores and older ages (12) . However, a recent study found different results and raised doubts about the safety of doripenem compared to that of imipenem in patients with Pseudomonas aeruginosa VAP (13) . Moreover, most studies that evaluated doripenem activity were in vitro studies, and uncertainty persists as to the capacity of a given carbapenem to select fewer carbapenem-resistant strains than another. In the Groupe Hospitalier Pitié-Salpêtrière, the three antipseudomonal carbapenems (imipenem, meropenem, and doripenem) are available and routinely prescribed by physicians in the two intensive care units (ICUs), where a local policy of mixing these three drugs is applied.
Therefore, we conducted a prospective, observational study on patients who developed Pseudomonas aeruginosa VAP (i) to determine the isolates' MICs for imipenem, meropenem, and doripenem, (ii) to determine factors and outcomes associated with carbapenem resistance, (iii) to determine factors associated with an unfavorable outcome, defined as death or VAP recurrence, and (iv) and to compare, according to the carbapenem received, the patients' outcomes and carbapenem resistance emergence for patients with recurrent Pseudomonas aeruginosa VAP.
MATERIALS AND METHODS
Patients. Consecutive patients that developed Pseudomonas aeruginosa VAP in two medicosurgical ICUs in the Groupe Hospitalier Pitié-Salpêtrière teaching hospital were prospectively enrolled. Patients were included when they were Ն18 years old, were mechanically ventilated, and had ventilator-associated pneumonia [defined as the presence of a new or progressive infiltrate(s) on a chest radiograph(s) after at least 48 h of mechanical ventilation (MV) and at least two of the following: (i) fever, defined as a core temperature of Ͼ38.3°C, or hypothermia, defined as a core temperature of Ͻ35.0°C; (ii) a leukocyte count of Ն11,000/mm 3 or Յ4,500/mm 3 ; or (iii) a new onset of purulent sputum production or respiratory secretions or a change of sputum characteristics (1) 6 CFU/ml]). This epidemiological study was conducted in accordance with the ethical standards of the Committee for the Protection of Human Research Subjects (CCP Île-de-France VI, Groupe Hospitalier Pitié-Salpêtrière, Paris, France). In accordance with French law, no informed consent was obtained because this study did not modify existing diagnostic or therapeutic strategies. However, the patients or their relatives received an information sheet describing the study and explaining that they were free to withdraw from it at any time.
Bacteriological procedures. (i) Susceptibility testing. Pseudomonas aeruginosa strains were isolated from respiratory specimens, and antibiotic susceptibilities were determined using the disk diffusion method. Mueller-Hinton agar and disks of antibiotics were purchased from Sanofi Pasteur Diagnostics (Marne La Coquette, France) and used according to the guidelines of the Antibiogram Committee of the French Society of Microbiology (CA-SFM). Strains responsible for the first and recurrent episodes were collected, frozen, and stored for future analysis. At the end of the study, all Pseudomonas aeruginosa isolates were subcultured, and imipenem, meropenem, and doripenem MICs were determined by Etest (bioMérieux, Marcy l'Etoile, France). Also, isolate susceptibilities to antibiotics were redetermined using the disk diffusion method in order to check the concordance with the initial determination. Carbapenem susceptibilities were defined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (http://www.eucast .org/clinical_breakpoints/; last accessed September 2013). Susceptibility breakpoints for imipenem, meropenem, and doripenem were Յ4, Յ2, and Յ1 mg/liter, respectively; resistance breakpoints were Ͼ8, Ͼ8, and Ͼ4 mg/ liter, respectively.
In patients with a recurrent episode, the emergence of carbapenem resistance was assessed with the following: the carbapenem resistance rate of the second strain, the percentage of strains with MICs Ͼ4-fold the MIC of the first strain, and susceptibility changes (from susceptible for the first strain to intermediate susceptible or resistant for the second strain or from intermediate susceptible for the first strain to resistant for the second strain).
Pseudomonas aeruginosa strains were classified as multidrug resistant (MDR), extensively drug resistant (XDR), and pandrug resistant (PDR), according to the classification proposed by Magiorakos et al. (15) : MDR Pseudomonas aeruginosa was defined as a strain with nonsusceptibility to Ն1 agent in Ն3 antimicrobial categories, XDR Pseudomonas aeruginosa was defined as a strain with nonsusceptibility to Ն1 agent in all but Յ3 categories, and PDR Pseudomonas aeruginosa was defined as a strain with nonsusceptibility to all agents.
(ii) Diversilab typing. To compare the Pseudomonas aeruginosa isolates responsible for the first and second episodes in the patients with a VAP recurrence, the corresponding strains were typed using the DiversiLab (bioMérieux) technology, which has been described elsewhere (16, 17) . Briefly, it uses a semiautomated, repetitive, DNA sequence-based PCR to characterize the genome, and good agreement has been found between it and pulsed-field gel electrophoresis for Pseudomonas aeruginosa strains (16, 17) .
All bacteriological procedures were processed blindly by the same investigators at the end of the study.
Antimicrobial treatment. Antimicrobial therapy for each VAP episode was chosen at the physician's discretion. Notably, the choice of antibiotic agent(s), combination therapy, administration route, and treatment duration was not standardized. In the Groupe Hospitalier Pitié-Salpêtrière, the three carbapenems (imipenem, meropenem, and doripenem) are available and are equally prescribed by physicians in the two ICUs, where a local policy of mixing these three drugs is applied. Thus, the physician could choose to treat patients with one of the three carbapenems. The doses were those recommended by the manufacturers of each drug: patients prescribed imipenem or meropenem received 1 g three times a day (t.i.d.) during a 1-h infusion, and those given doripenem received 500 mg t.i.d. during a 4-h infusion, after they had received a 1-g loading dose. In the case of renal failure, doses were adapted to renal function. When the Pseudomonas aeruginosa strains were susceptible, the decision of whether or not to use antibiotic deescalation and its timing were left to the physician's discretion. The duration of antimicrobial treatment was also left to the physician's discretion.
Appropriate antibiotic therapy included the administration of at least one antibiotic with in vitro activity against the bacterial pathogens isolated (from blood, BAL fluid [Ն10 4 CFU/ml], mini-BAL fluid [Ն10 3 CFU/ml], or tracheal aspirate [Ն10 6 CFU/ml]) (18) . Patients were considered to have received definitive combination therapy when they were given two or more drugs active against all microorganisms for Ն5 days.
Data collection. At ICU admission, the following data were recorded: age, sex, comorbidities, severity of underlying medical condition according to the McCabe and Jackson criteria (19) , simplified acute physiology score (SAPS) II (20), sequential organ failure assessment (SOFA) score (21) , admission category, and the primary reason for MV. On the day of VAP diagnosis (day 1) and on day 7, the following were recorded: duration of previous MV, the antibiotic(s) received before VAP onset, temperature, leukocyte count, arterial partial pressure of oxygen/fraction of inspired oxygen (PaO 2 /FIO 2 ) ratio, tracheal aspirate aspect, radiological score (22), SOFA score, and the presence of the acute respiratory distress syndrome (ARDS) (23) . Moreover, the clinical pulmonary infection score, based on five variables (temperature, blood leukocytes, tracheal secretions, oxygenation [PaO 2 /FIO 2 ratio], and pulmonary radiography), was calculated (24) . Patients were followed until death or ICU discharge.
Follow-up. Extreme vigilance for pneumonia recurrence was maintained throughout the study to detect any possible recurrence or new episode of pulmonary infection (patients were assessed at least 3 times a day), and pulmonary or tracheal secretions were collected (by fiberoptic bronchoscopy with BAL or mini-BAL or by TA, respectively) from patients before any new antibiotics were started or as soon as they became febrile (temperature Ն 38.3°C) or had purulent tracheal secretions, a new pulmonary infiltrate(s), or progression of an existing infiltrate. Tracheal or pulmonary secretions were also collected when unexplained hemodynamic instability required higher vasopressor doses (Ͼ30%) or their introduction, in the case of unexplained deterioration of blood gases with a Ͼ30% PaO 2 /FIO 2 decrease, or when an intercurrent event imposed an urgent antibiotic therapy change, regardless of the reason (1).
Recurrence was defined as the persistence or reappearance of clinical and biological signs of infection and significant concentrations of Pseudomonas aeruginosa in lower respiratory tract specimens at least 2 days (but no more than after 28 days) after completing antibiotic therapy for the first episode.
Pseudomonas aeruginosa VAP recurrence or an in-ICU death was defined as an unfavorable outcome.
Statistical analyses. Data are expressed as medians (25 to 75th percentiles) for nonnormally distributed variables and means Ϯ standard deviations for normally distributed variables, unless specified otherwise, and were compared as follows: continuous variables with the Mann-Whitney U test, Student's t test, Friedman test, or Wilcoxon test, as appropriate, and categorical variables with the chi-square test. A P value of Ͻ0.05 was defined as statistical significance. We performed univariable and multivariable analyses to determine factors associated with carbapenem resistance or an unfavorable outcome. Prognostic variables associated with carbapenem resistance in our univariable analysis with P values of Ͻ0.1 were introduced into a multivariable logistic regression model using backward stepwise variable elimination (with a variable exit threshold at a P value of Ͼ0.05) to estimate the odds ratio (OR) for carbapenem resistance. The same methodology was used to estimate the OR for unfavorable outcomes.
RESULTS
One-hundred seventy-four patients were enrolled over an 18-month period in two ICUs (83 in the medical ICU and 91 in the multidisciplinary ICU). Among them, five Pseudomonas aeruginosa strains could not be recovered from storage and the patients were excluded from the study (Fig. 1) . The admission and day 1 characteristics of the 169 patients are reported in Table 1 . None of these patients were neutropenic. Among these 169 Pseudomonas aeruginosa VAP episodes, 44 (26%) were a constituent of polymicrobial infection, and 10 (6%) patients had Pseudomonas aeruginosa-positive blood cultures. Thirty-six (21%) strains were MDR, 18 (11%) were XDR, and none were PDR.
Carbapenem MICs. Carbapenem MIC distributions for strains responsible for the first VAP episode are given in Fig. 2 and Table 2 . Doripenem MICs were significantly lower (P Ͻ 0.0001) than those of imipenem or meropenem, and meropenem MICs were significantly lower (P Ͻ 0.0001) than those of imipenem. Factors associated with carbapenem resistance. Patients' baseline and day 1 characteristics according to carbapenem susceptibility are given in Table S1 in the supplemental material. According to our multivariable analyses, the only factors independently associated with carbapenem intermediate susceptibility or resistance were carbapenem use within the preceding 15 days and MV duration before VAP onset (Table S1 in the supplemental material).
Factors associated with unfavorable outcome. Patients' outcomes are given in Table 3 and Fig. 1 : 56 (33%) patients died, 56 (33%) had at least one recurrence, and 92 (54%) had unfavorable outcomes, defined as recurrence or in-ICU death. The DiversiLab technology indicated that isolates responsible for the first and recurrent episodes were the same in 36 (64%) patients and differed in 20 (34%).
Factors associated with an unfavorable outcome are listed in Table S2 in the supplemental material. Multivariable analyses retained only the day 7 SOFA score and persistent MV after day 7 as being independently associated with an unfavorable outcome. Neither the carbapenem resistance of the Pseudomonas aeruginosa strains responsible for the first VAP episode nor the use of a carbapenem to treat the first episode was associated with an unfavorable outcome. Moreover, multidrug or extensive drug resistance was not associated with an unfavorable outcome.
Carbapenem-treated patients. Among the 169 patients, 88 (52%) were treated with a carbapenem: 32 with imipenem, 24 with meropenem, and 32 doripenem (Fig. 1) . Of these 88, all but 11 (4 treated with imipenem, 4 treated with meropenem, and 3 treated with doripenem) received combination therapy with either aminoglycosides or a fluoroquinolone for at least 2 days. The remaining 81 patients received various antibiotics, including short-term carbapenem (Յ3 days), followed by either deescalation (n ϭ 6) or antibiotic changes because the strains were not susceptible to carbapenem (n ϭ 4). Among the imipenem-treated patients, seven (22%) were infected with strains exhibiting decreased imipenem susceptibility: five imipenem-resistant and two imipenem-intermediate-susceptible strains, as determined by the MIC cutoffs. Two of them died on day 2, before culture results became available. Three had VAP due to XDR strains and received imipenem plus ciprofloxacin, fosfomycin, or nebulized colistin; all 3 ultimately died. Two patients' strains were initially considered imipenem susceptible using the standard method of determi- nation (disk diffusion method), but MIC determinations yielded different results; both patients experienced VAP recurrences. Among the 25 patients who had IMP-susceptible strain, 9 died and 4 had a VAP recurrence. Among the meropenem-treated patients, two (8%) were infected with meropenem-resistant strains, as determined by MIC cutoffs. The first died on day 3, before the susceptibility results became available, and the second had an MDR strain and received inhaled colistin as adjunctive therapy. This patient had a favorable outcome. Among the 22 patients who had meropenem-susceptible strains, 5 died and 3 had VAP recurrence.
Among the doripenem-treated patients, six (19%) were infected with doripenem-intermediate-susceptible strains, as determined by MIC cutoffs. One died on day 4, before the susceptibility results became available. Five had VAP due to MDR strains; four of them received aerosolized colistin or prolonged aminoglycoside administration (4 days), in addition to doripenem (2 had favorable outcomes, 1 had a VAP recurrence, and 1 died), and one When outcome analysis was restricted to the carbapenemtreated 88 patients, the independent factors associated with an unfavorable outcome were the presence of ARDS at VAP onset, the day 7 SOFA score, persistent MV after day 7, and infection with an MDR strain ( Table 4) .
Emergence of carbapenem resistance. When analyzing the strains responsible for VAP recurrence in the 88 carbapenemtreated patients, carbapenem resistance emergence was the same for patients treated with imipenem, meropenem, or doripenem. The carbapenem resistance rate of the second strain, the percentage of strains with a MIC Ͼ4-fold that for the first strain, and susceptibility changes (from susceptible for the first strain to intermediate susceptible or resistant for the second strain or from intermediate susceptible for the first strain to resistant for the second strain) were similar for the 3 carbapenems (Table 5) . However, among the 16 strains initially imipenem susceptible but subsequently imipenem resistant, meropenem and doripenem were still active for one and two strains, respectively; notably, the reverse situation was not observed.
DISCUSSION
The results of this large, prospective, observational study showed that Pseudomonas aeruginosa strains responsible for VAP had lower doripenem MICs than imipenem or meropenem MICs. Moreover, 40% of the strains were carbapenem intermediate susceptible or resistant. Factors independently associated with carbapenem resistance were carbapenem use during the preceding 15 days and MV duration. Factors associated with an unfavorable outcome were the need for Ͼ7 days of MV and day 7 SOFA scoredetermined disease severity. Analysis of strains responsible for VAP recurrences showed 64% to be the same as the first episode (25) . On the basis of their determined doripenem, imipenem, and meropenem MICs, doripenem was more active than imipenem or meropenem, with doripenem susceptibility observed for some imipenem-resistant and/or meropenem-resistant isolates. Our results were similar not only for the isolates causing the first episodes but also for those responsible for the recurrences. As previously described, we also observed that factors associated with infection with a carbapenem-resistant strain were prior carbapenem use and prolonged MV duration (26) . The rate of superinfection observed in our study was also similar to that observed in others (27, 28) .
As previously reported (29), we, too, found that factors associated with an unfavorable outcome were SOFA score-assessed day 7 disease severity and the persistent need for MV on day 7. Neither the use of combination therapy nor the duration of antimicrobial treatment was independently associated with an unfavorable outcome. These findings are in accordance with those from previously published studies: even in Pseudomonas aeruginosa VAP, neither long (as opposed to short) treatment duration nor combination therapy was associated with better outcomes (30) (31) (32) , and the resistance of the strain was also not associated with treatment failure (33) . Notably, when we restricted this analysis to the 88 carbapenem-treated patients, the same factors were retained (in addition to ARDS on day 1) as being associated with an unfavorable outcome, as was the resistance of the strains.
Only a few studies have compared one carbapenem to another, and the results differed. In a double-blind, randomized controlled trial, Chastre et al. evaluated doripenem versus imipenem treatment of VAP (12) . In that study, doripenem was found to be noninferior to imipenem, with the clinical cure rate tending to be higher in patients with Pseudomonas aeruginosa VAP (80% versus 42.9%, respectively; P was not significant). In another doubleblind, randomized trial, Kollef et al. compared a 7-days course of doripenem (1 g infused over 4 h t.i.d.) to a 10-day course of imipenem (1 g infused over 1 h t.i.d.) for patients with VAP (13). They found that doripenem-arm patients had nonsignificantly higher clinical failure and mortality rates. Moreover, the day 28 mortality rate was significantly higher for doripenem-arm than imipenemarm patients with Pseudomonas aeruginosa VAP. In that study, an insufficient doripenem treatment duration and/or subtherapeutic doripenem concentrations in patients with elevated creatinine clearance were deemed responsible for the poor outcomes of the doripenem-treated patients (13) . Although our results do not come from a randomized controlled trial, more Pseudomonas aeruginosa VAP cases were included; nonetheless, we were unable to find any clinical differences among patients according to the carbapenem received.
To the best of our knowledge, the emergence of carbapenem resistance among Pseudomonas aeruginosa isolates as a function of the carbapenem received has not been examined previously. However, in their randomized trial evaluating doripenem versus imipenem treatment of VAP, Chastre et al. looked at the carbapenem susceptibility changes of their Pseudomonas aeruginosa isolates as a function of the carbapenem received (12) . Notably, decreased susceptibility (i.e., a MIC increase Ն4 times the baseline MIC) of repeat cultures was observed in 10 (35.7%) of the 28 doripenemarm patients whose baseline isolates were doripenem susceptible and 10 (53%) of the 19 imipenem-arm patients whose baseline isolates were imipenem susceptible (P was not significant) (12) . In the present study, regardless of the carbapenem received, similar percentages of isolates responsible for the second episode had diminished susceptibilities.
Our study has several limitations that should be mentioned. First, it was not a randomized controlled trial but an observational study; thereby, no conclusion about the absence of differences among clinical outcomes when using one carbapenem or another can be firmly drawn. However, this was a large study, and its findings should be taken into account in the global discussion of the superiority (or inferiority) of one carbapenem or another. Second, because only two ICUs in the same hospital participated in this study, extrapolating our results to other ICUs with different microecologies is difficult. Third, the number of patients treated with each carbapenem was relatively small, and thus, the study might have been underpowered to reveal some risk factors for carbapenem resistance, unfavorable outcome, or resistance emergence during treatment. Last, because repeat isolates were not available from patients who died, we cannot rule out the possibility that patients who died may have had a VAP recurrence caused by carbapenem-resistant strains.
In conclusion, our results show that, among patients with Pseudomonas aeruginosa VAP, isolate MICs were lower for doripenem than imipenem or meropenem, and 40% of the strains were carbapenem intermediate susceptible or resistant. In patients treated with a carbapenem, no outcome differences were observed, regardless of the carbapenem prescribed. Pertinently, in the case of recurrence, some imipenem-resistant strains remained meropenem susceptible and/or doripenem susceptible, supporting susceptibility testing for these two carbapenems in this setting.
